Diosmin anti-tumour efficacious against Hepatocellular Carcinoma

The present study absorbed the anti-cancer activity of diosmin at 50, 100, 150, 200 μM/ml for 24h of treatment
on dose dependent manner. Group II animals were dministrated 0.01% NDEA to induce primary liver
carcinoma. Cancer bearing experimental animals were treated orally with the drug diosmin at the dosage level of
200 mg per kg/bodyweight for 28 successive days. Results: Diosmin treatment on HepG2 cells constrains nearly
half of the cell population and proliferation at the dose of 100 μM/ml and in vivo experimental studies showed
remarkable repossession in biochemical and morphological characteristics. These results summarizes that both in
vivo and in vitro anti-carcinogenic activity of diosmin could be an outstanding flavonoid in the treatment of HCC
because of its therapeutic and pharmacological properties.